Research analysts covering Abivax.
Recent press releases and 8-K filings for ABVX.
Abivax Discusses Positive Oripazimod Phase III Data at UEG Conference
ABVX
Product Launch
New Projects/Investments
- Abivax presented positive oripazimod Phase III data at the UEG conference, demonstrating its efficacy in inducing remission across both naive and highly refractory ulcerative colitis patient populations.
- The primary outcome metric showed a 16% delta for the 50mg dose and 13% for the 25mg dose between effective arms and placebo, with significant clinical remission and endoscopic improvement, particularly in refractory patients.
- The company plans to release top-line quality of life data in November, along with biomarker and clinical combination data in the coming months.
- Market research indicates a potential 32% market share in the refractory population and 15% in the naive population, with a potential market expansion of up to 100,000 patients in the US.
Oct 6, 2025, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more